Alan A. Steigrod
Corporate Officer/Principal at Newport Health Care Ventures
Profile
Alan A.
Steigrod has been a Director of Sepracor, Inc. since 1995 and is a Member of the Audit Committee, the Nominating Committee and the Corporate Governance Committee.
He has been Managing Director of Newport HealthCare Ventures since January 1996.
Mr. Steigrod is a Director of NeoRx Corp.
and Lorus Therapeutics, Inc. Previously, he was President and Chief Executive Officer of Cortex Pharmaceuticals, Inc. from March 1993 to November 1995, President of Alan Steigrod Consulting from February 1991 to February 1993 and an Executive Vice President of Marketing and Sales for Glaxo, Inc. from March 1981 to February 1991.
Alan A. Steigrod active positions
| Companies | Position | Start |
|---|---|---|
| Newport Health Care Ventures | Corporate Officer/Principal | 1995-12-31 |
Former positions of Alan A. Steigrod
| Companies | Position | End |
|---|---|---|
Sumitomo Pharma America, Inc.
 Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Director/Board Member | 2009-10-19 |
Cellegy Pharmaceuticals, Inc.
 Cellegy Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cellegy Pharmaceuticals specialty biopharmaceutical company, that is primarily engaged in the development and commercialization of prescription drugs targeting women’s health care, including reduction in transmission of HIV and female sexual dysfunction, and gastrointestinal conditions using proprietary topical formulations and nitric oxide, or NO, donor technologies | Director/Board Member | 2009-04-21 |
| PONIARD PHARMACEUTICALS, INC. | Director/Board Member | 2006-08-15 |
| RESPIRERX PHARMACEUTICALS INC. | President | 1995-10-31 |
| Alan Steigrod Consulting | President | 1993-01-31 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| PONIARD PHARMACEUTICALS, INC. | Health Technology |
| RESPIRERX PHARMACEUTICALS INC. | Health Technology |
| APTOSE BIOSCIENCES INC. | Health Technology |
| Private companies | 5 |
|---|---|
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Health Technology |
Cellegy Pharmaceuticals, Inc.
Cellegy Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cellegy Pharmaceuticals specialty biopharmaceutical company, that is primarily engaged in the development and commercialization of prescription drugs targeting women’s health care, including reduction in transmission of HIV and female sexual dysfunction, and gastrointestinal conditions using proprietary topical formulations and nitric oxide, or NO, donor technologies | Health Technology |
| Newport Health Care Ventures | |
| Glaxo, Inc. | |
| Alan Steigrod Consulting |
- Stock Market
- Insiders
- Alan A. Steigrod
